



Name	Hye Won Lee
Affiliation	Yonsei University College of Medicine
Country	Korea
Major Field	Hepatology

Educational Background	
1998-2003	Bachelor Degree, Yonsei University College of Biochemistry, Seoul, Korea
2005-2009	Bachelor Degree, Ewha Womans University College of Medicine, Seoul, Korea
2013-2017	Ph.D. Course of Medical Science, Yonsei University College of Medicine, Seoul, Korea

Professional Experience	
2009 – 2010	Internship, Severance Hospital, Seoul, Korea
2010 – 2014	Residency, Severance Hospital, Seoul, Korea
2014 – 2015	Clinical and Research Fellowship, Severance Hospital, Seoul, Korea
2015 – 2018	Clinical and Research Assistant Professor, Severance Hospital, Seoul, Korea
2018 – 2019	Visiting Scholar, The Chinese University of Hong Kong, Hong Kong
2020 – 2023	Assistant Professor Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2024 – Present	Associate Professor Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea



Main Scientific Publications

1. Rabbat J, Yang B, **Lee HW**, Lin H, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Fournier-Poizat C, Wong GL, Zoncape M, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gomez M, Wong VW, Kim SU, Yip TC. Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement. *Clin Mol Hepatol*. 2025 Nov 11
2. **Lee HW**, Lee JS, Kim MN, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease. *Clin Mol Hepatol*. 2025 Jul;31(3):1018-1031
3. Lai JC, Yang B, **Lee HW**, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. *Gut*. 2025 Jun 20:gutjnl-2025-33498
4. Park K, **Lee HW**, Kim E, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Ryoo BY, Han S, Choi J. Risk of Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab Treatment for Hepatocellular Carcinoma. *Aliment Pharmacol Ther*. 2025 Jan 28. doi: 10.1111/apt.18526
5. Cheuk-Fung Yip T, **Lee HW**, Lin H, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Boon-Bee Goh G, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Fournier-Poizat C, Lai-Hung Wong G, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Jun Teh KK, Lara-Romero C, Asgharpour A, Mahgoub S, Sau-Wai Chan M, Canivet CM, Romero-Gomez M, Kim SU, Wai-Sun Wong V. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. *J Hepatol*. 2025 Jan 23: S0168-8278(25)00021-2.
6. H Lin, **HW Lee**, TCF Yip, E Tsochatzis, S Petta, et al. Vibration-controlled transient Elastography scores to predict liver-related events in Steatotic liver disease. *JAMA*. 2024 Mar 21:e241447.